Literature DB >> 27206275

Pulmonary Vascular Dysfunction and Cor Pulmonale During Acute Respiratory Distress Syndrome in Sicklers.

Jérôme Cecchini1, Florence Boissier, Aude Gibelin, Nicolas de Prost, Keyvan Razazi, Guillaume Carteaux, Frederic Galacteros, Bernard Maitre, Christian Brun-Buisson, Armand Mekontso Dessap.   

Abstract

BACKGROUND: Acute chest syndrome (ACS) is the most common cause of death among sickle cell disease (SCD) adult patients. Pulmonary vascular dysfunction (PVD) and acute cor pulmonale (ACP) are common during acute respiratory distress syndrome (ARDS) and their prevalence may be even more important during ARDS related to ACS (ACS-ARDS). The objective of this study was to evaluate the prevalence and prognosis of PVD and ACP during ACS-ARDS. PATIENTS AND METHODS: This was a retrospective analysis over a 10-year period of patients with moderate-to-severe ARDS. PVD and ACP were assessed by echocardiography. ARDS episodes were assigned to ACS-ARDS or nonACS-ARDS group according to whether the clinical insult was ACS or not, respectively. To evaluate independent factors associated with ACP, significant univariable risk factors were examined using logistic regression and propensity score analyses.
RESULTS: A total of 362 patients were analyzed, including 24 ACS-ARDS. PVD and ACP were identified, respectively, in 24 (100%) and 20 (83%) ACS-ARDS patients, as compared with 204 (60%) and 68 (20%) nonACS-ARDS patients (P < 0.0001). The mortality did not differ between ACS-ARDS and nonACS-ARDS patients. Both the crude (odds ratio [OR], 19.9; 95% confidence interval [CI], 6.6-60; P < 0.0001), multivariable adjustment (OR, 27.4; 95% CI, 8.2-91.5; P < 0.001), and propensity-matched (OR, 11.7; 95% CI, 1.2-110.8; P = 0.03) analyses found a significant association between ACS-ARDS and ACP.
CONCLUSIONS: All SCD patients presenting with moderate-to-severe ARDS as a consequence of ACS experienced PVD and more than 80% of them exhibited ACP. These results suggest a predominant role for PVD in the pathogenesis of severe forms of ACS.

Entities:  

Mesh:

Year:  2016        PMID: 27206275     DOI: 10.1097/SHK.0000000000000640

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

Review 1.  The use of echocardiographic indices in defining and assessing right ventricular systolic function in critical care research.

Authors:  Stephen J Huang; Marek Nalos; Louise Smith; Arvind Rajamani; Anthony S McLean
Journal:  Intensive Care Med       Date:  2018-05-22       Impact factor: 17.440

2.  Ten tips for managing critically ill patients with sickle cell disease.

Authors:  Armand Mekontso Dessap; M Fartoukh; R F Machado
Journal:  Intensive Care Med       Date:  2016-08-04       Impact factor: 17.440

Review 3.  Diagnostic workup, etiologies and management of acute right ventricle failure : A state-of-the-art paper.

Authors:  Antoine Vieillard-Baron; R Naeije; F Haddad; H J Bogaard; T M Bull; N Fletcher; T Lahm; S Magder; S Orde; G Schmidt; M R Pinsky
Journal:  Intensive Care Med       Date:  2018-05-09       Impact factor: 17.440

Review 4.  Acute cor pulmonale in patients with acute respiratory distress syndrome: A comprehensive review.

Authors:  Kay Choong See
Journal:  World J Crit Care Med       Date:  2021-03-09

5.  Endothelial dysfunction and hypercoagulability in severe sickle-cell acute chest syndrome.

Authors:  Etienne-Marie Jutant; Guillaume Voiriot; Vincent Labbé; Laurent Savale; Hayat Mokrani; Patrick Van Dreden; Grigorios Gerotziafas; Muriel Fartoukh
Journal:  ERJ Open Res       Date:  2021-12-13

6.  Lower respiratory tract infection with Staphylococcus aureus in sickle-cell adult patients with severe acute chest syndrome - the STAPHACS Study.

Authors:  Alexandre Elabbadi; Guillaume Voiriot; Anne Tristan; Aude Gibelin; Charlotte Verdet; Michel Djibré; Aline Santin; Etienne-Marie Jutant; Julien Lopinto; François Vandenesch; François Lionnet; Muriel Fartoukh
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.